Sep 12, 2023 / 04:55PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Okay. Thanks so much for joining us, everybody. I'm Terence Flynn, U.S. biopharma analyst here at Morgan Stanley and very pleased to be hosting Royalty Pharma today. Joining us from the company, we have Pablo Legorreta, who is the company's founder and CEO; and Terry Coyne, the company's CFO. Thank you both so much for being here.
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Thanks so much both for being here. Really appreciate the time today. Maybe Pablo, I thought just to share a little bit of background of the company and the business model, because it is somewhat unique for those who are new to the story, and then we can dive into some of the more detailed questions.
Pablo Legorreta - Royalty Pharma plc
Royalty Pharma PLC at Morgan Stanley Global Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers